Qiang Lu1, Jiamin Xu2, Qian Li3,4,5, Wenzhen Wu2, Yuling Wu2, Jianhui Xie3,4,5, Xiaobo Yang3,4,5. 1. Department of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, China. 2. The Second School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China. 3. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China. 4. State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China. 5. Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou 510120, China.
Abstract
BACKGROUND: Safflower injection (SFI), a popular Chinese patent drug, is commonly used to treat acute coronary syndromes (ACSs) in China. The research seeks to scientifically estimate the clinical efficacy of SFI for ACS patients. METHODS: Eight electronic databases were retrieved for eligible research from the founding date to September 8, 2020. Odds ratio (OR) was adopted to assess the total effective rate, ECG improvement, and adverse reaction, and mean difference (MD) was used for assessing the hemorheology indexes as well as the LVEF. RESULTS: Sixteen randomized controlled trials involving 1620 sufferers with ACS were incorporated. The outcomes showed that, in comparison to conventional medication alone, SFI combined with conventional treatment remarkably enhanced the total effective rate (OR = 3.66, 95% CI [2.73, 4.90], P < 0.00001), ECG improvement (OR = 2.85, 95% CI [2.04, 3.99], P < 0.00001), and LVEF (MD = 5.13, 95% CI [3.73, 6.53], P < 0.00001). Moreover, SFI combined with conventional treatment significantly decreased hemorheology indexes including BV (MD = -0.95, 95% CI [-1.76, -0.13], P=0.02), HCT (MD = -2.37, 95% CI [-3.25, -1.50], P < 0.00001), FIB (MD = -0.44, 95% CI [-0.60, -0.29], P < 0.00001), and PAR (OR = -7.65, 95% CI [-10.16, -5.14], P < 0.00001). However, no notable contrast was observed to link the experimental and the control team for PV (MD = -0.42, 95% CI [-0.83, 0.00], P=0.05) and adverse reactions (OR = 0.59, 95% CI [0.13, 2.74], P=0.50). CONCLUSION: Despite the limitations that existed in this meta-analysis, the outcomes demonstrated that SFI and conventional combined medication is an effective and relatively safe therapy for ACS sufferers.
BACKGROUND: Safflower injection (SFI), a popular Chinese patent drug, is commonly used to treat acute coronary syndromes (ACSs) in China. The research seeks to scientifically estimate the clinical efficacy of SFI for ACS patients. METHODS: Eight electronic databases were retrieved for eligible research from the founding date to September 8, 2020. Odds ratio (OR) was adopted to assess the total effective rate, ECG improvement, and adverse reaction, and mean difference (MD) was used for assessing the hemorheology indexes as well as the LVEF. RESULTS: Sixteen randomized controlled trials involving 1620 sufferers with ACS were incorporated. The outcomes showed that, in comparison to conventional medication alone, SFI combined with conventional treatment remarkably enhanced the total effective rate (OR = 3.66, 95% CI [2.73, 4.90], P < 0.00001), ECG improvement (OR = 2.85, 95% CI [2.04, 3.99], P < 0.00001), and LVEF (MD = 5.13, 95% CI [3.73, 6.53], P < 0.00001). Moreover, SFI combined with conventional treatment significantly decreased hemorheology indexes including BV (MD = -0.95, 95% CI [-1.76, -0.13], P=0.02), HCT (MD = -2.37, 95% CI [-3.25, -1.50], P < 0.00001), FIB (MD = -0.44, 95% CI [-0.60, -0.29], P < 0.00001), and PAR (OR = -7.65, 95% CI [-10.16, -5.14], P < 0.00001). However, no notable contrast was observed to link the experimental and the control team for PV (MD = -0.42, 95% CI [-0.83, 0.00], P=0.05) and adverse reactions (OR = 0.59, 95% CI [0.13, 2.74], P=0.50). CONCLUSION: Despite the limitations that existed in this meta-analysis, the outcomes demonstrated that SFI and conventional combined medication is an effective and relatively safe therapy for ACS sufferers.
Authors: E Braunwald; E M Antman; J W Beasley; R M Califf; M D Cheitlin; J S Hochman; R H Jones; D Kereiakes; J Kupersmith; T N Levin; C J Pepine; J W Schaeffer; E E Smith; D E Steward; P Theroux; J S Alpert; K A Eagle; D P Faxon; V Fuster; T J Gardner; G Gregoratos; R O Russell; S C Smith Journal: J Am Coll Cardiol Date: 2000-09 Impact factor: 24.094
Authors: Hugo Katus; André Ziegler; Okan Ekinci; Evangelos Giannitsis; Wendy Gattis Stough; Stephan Achenbach; Stefan Blankenberg; Martina Brueckmann; Paul Collinson; Dorin Comaniciu; Filippo Crea; Wilfried Dinh; Grégory Ducrocq; Frank A Flachskampf; Keith A A Fox; Matthias G Friedrich; Kathy A Hebert; Anders Himmelmann; Mark Hlatky; Dominik Lautsch; Bertil Lindahl; Daniel Lindholm; Nicholas L Mills; Giorgio Minotti; Martin Möckel; Torbjørn Omland; Véronique Semjonow Journal: Eur Heart J Date: 2017-11-01 Impact factor: 29.983